Hepion Pharmaceuticals Gains FDA Backing for GV104 Modeling

Regulatory affairs leads tracking non-traditional NDA pathways should note that Hepion Pharmaceuticals has received written FDA feedback affirming a modeling-and-simulation approach as the primary evidentiary basis for GV104, a 16 mg nalmefene buccal film intended as a prophylactic countermeasure against fentanyl-induced cardiac arrest. The agency's position, communicated in response to a July 2026 briefing package, reinforces the viability of computational surrogates in lieu of conventional clinical challenge studies for this program.

The expanded analysis, conducted by Hepion's subsidiary Gravitas Life Sciences, combined population pharmacokinetics with a physiological opioid overdose model originally developed by FDA researchers. Simulations across 200 virtual subjects showed that a single GV104 dose taken at least 15 minutes before exposure prevented every simulated fentanyl-induced cardiac arrest at intravenous doses two to seven times those used for pain relief. At the highest fentanyl dose modeled, 86.5 percent of untreated virtual subjects were projected to develop cardiac arrest. Protection onset was predicted at a median of 10 to 15 minutes post-dose, an improvement over the 30-minute estimate published in 2025. Comparable results were observed in simulated subjects with high lean-body-mass, reflecting the military and first-responder target population.

FDA's written comments addressed model structure, results presentation, and fentanyl challenge simulation design. The agency stated that incorporating these revisions will improve Hepion's ability to demonstrate long-term prophylactic protection. Hepion characterizes each comment as addressable within its existing modeling program and intends to respond promptly. Importantly, predicted onset, duration, and degree of protection remain subject to revision pending that response.

The program is advancing under a 505(b)(2) NDA framework, relying in part on FDA's prior findings for an approved injectable nalmefene product. In March 2025, the agency stated that additional clinical studies do not appear necessary to define the prophylactic dosing window, a position that meaningfully narrows the remaining clinical burden. The principal outstanding workstream before an NDA filing is the Chemistry, Manufacturing and Controls program, which will require close attention from manufacturing and QA functions as the submission timeline firms up.

The CMC program's completion will be the measurable checkpoint determining when Hepion can move from modeling validation to a formal NDA filing.

Source: Hepion Pharmaceuticals via ACCESS Newswire, October 26, 2026.